Abstracts

Severe Neutropenia in HIV-Infected People on Antiretroviral Therapy in West Africa

In Sub-Saharan Africa, antiretroviral therapy (ART) with potential toxicity such as Zidovudine (AZT) is still massively prescribed in HIV-infected patients. Nevertheless, little information is available on adverse drug reactions such as neutropenia in real life conditions. This study aimed at estimating the incidence of severe neutropenia and associated factors after ART initiation in five West…

Efavirenz Toxicity Manifesting As Cerebellar Ataxia: Case Series From South Africa

WHO treatment guidelines  recommend efavirenz (EFV) as the backbone of first line antiretroviral therapy (ART). Fixed dose combination (FDC), which contain efavirenz 600mg,  improve adherence but dose adjustments cannot be made easily. EFV commonly causes early neuro-psychiatric adverse events.  We present seven cases with late EFV toxicity causing severe cerebellar ataxia.  Consecutive HIV-infected adults taking…

Utility of the 1% HIV Prevalence Threshold in Defining Concentrated HIV Epidemics

Regions with HIV prevalence < 1% are defined as experiencing ‘concentrated’ HIV epidemics, with larger epidemics labeled as ‘generalized’. The surveillance and prevention implications include prioritizing resources on key populations (e.g. persons engaged in sex work [SW]) in ‘concentrated’ epidemics or on the general population otherwise. We hypothesize that the 1% threshold does not distinguish…